Based on our data, tumor cells enriched in M and G1 phases of the cell cycle might be more vulnerable to PI3K targetted therapies, e.g., alpelisib (BYL-719), in HR+, HER2−, and PIK3CA mutated advanced breast cancers (Narayan et al.,, 2021). This evidence concerns the gene HR and neoplasm.